Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Schwenk

Showing results (1-10 of 32) with videos related to

Pageof 4
Sort By:
Kidney360|January 18, 2024
Carboplatin Dosing on the Basis of Renal Function: 30+ Years after CalvertMichael H Schwenk
Pharmacotherapy|December 25, 2009
Ferumoxytol: a new intravenous iron preparation for the treatment of iron deficiency anemia in patients with chronic kidney diseaseMichael H Schwenk
Neural Computation|August 23, 2000
Boosting neural networksH Schwenk, Y Bengio
The Annals of Pharmacotherapy|October 1, 1995
Comment: piperacillin/tazobactam: a new beta-lactam/beta-lactamase inhibitor combinationF Wang, M H Schwenk
The New England Journal of Medicine|July 9, 2003
Eplerenone in patients with left ventricular dysfunctionDaniel A Blaustein, Michael H Schwenk
Clinical Nephrology|October 29, 1997
"Beer potomania" in a non-beer drinkerD A Blaustein, M H Schwenk
Advances in Chronic Kidney Disease|March 17, 2016
Drug Transporter Function--Implications in CKDMichael H Schwenk, Amy Barton Pai
Clinical Nephrology|September 11, 2004
Rapid, high-dose intravenous iron sucrose therapy in 2 Jehovah's Witness patients with severe anemia, iron deficiency and chronic kidney diseaseM H Schwenk, D A Blaustein
DICP : the Annals of Pharmacotherapy|July 1, 1989
Recombinant human erythropoietinM H Schwenk, C E Halstenson
Kidney International|June 1, 2012
Should mycophenolate mofetil replace cyclophosphamide as first-line therapy for severe lupus nephritis?Jonathan Hogan, Michael H Schwenk, Jai Radhakrishnan
Pageof 4

Showing results (1-10 of 32) with videos related to

Sort By:
Pageof 4
Kidney360|January 18, 2024
Carboplatin Dosing on the Basis of Renal Function: 30+ Years after CalvertMichael H Schwenk
Pharmacotherapy|December 25, 2009
Ferumoxytol: a new intravenous iron preparation for the treatment of iron deficiency anemia in patients with chronic kidney diseaseMichael H Schwenk
Neural Computation|August 23, 2000
Boosting neural networksH Schwenk, Y Bengio
The Annals of Pharmacotherapy|October 1, 1995
Comment: piperacillin/tazobactam: a new beta-lactam/beta-lactamase inhibitor combinationF Wang, M H Schwenk
The New England Journal of Medicine|July 9, 2003
Eplerenone in patients with left ventricular dysfunctionDaniel A Blaustein, Michael H Schwenk
Clinical Nephrology|October 29, 1997
"Beer potomania" in a non-beer drinkerD A Blaustein, M H Schwenk
Advances in Chronic Kidney Disease|March 17, 2016
Drug Transporter Function--Implications in CKDMichael H Schwenk, Amy Barton Pai
Clinical Nephrology|September 11, 2004
Rapid, high-dose intravenous iron sucrose therapy in 2 Jehovah's Witness patients with severe anemia, iron deficiency and chronic kidney diseaseM H Schwenk, D A Blaustein
DICP : the Annals of Pharmacotherapy|July 1, 1989
Recombinant human erythropoietinM H Schwenk, C E Halstenson
Kidney International|June 1, 2012
Should mycophenolate mofetil replace cyclophosphamide as first-line therapy for severe lupus nephritis?Jonathan Hogan, Michael H Schwenk, Jai Radhakrishnan
Pageof 4